Sobi Acquires Arthrosi Therapeutics in $1.5 Billion Deal
STOCKHOLM, December 13, 2025 – Swedish biopharmaceutical company Sobi® (STO: SOBI) has announced a definitive agreement to acquire Arthrosi Therapeutics, Inc., a U.S.-based late-stage biotechnology company developing innovative therapies for gout. The strategic acquisition is valued at up to $1.5 billion and marks a major expansion of Sobi’s presence in inflammatory and rare disease treatment, … Read more